Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, like its own Piqray, target tumors driven to growth by PIK3CA mutations.
Clinically meaningful activity was observed in 57 patients at 400 mg BID fed, including 11.1-month median PFS and mutation-subtype–agnostic benefit across kinase versus nonkinase PIK3CA variants.
In this study, researchers aimed to characterize the mutational landscape of the tumors of domestic cats to determine whether similarities to humans could translate to the clinic.
Scientists have mapped the genetics of cancer in cats for the first time at scale, uncovering major overlaps with human ...
Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + ...
A large new study has made an exciting discovery about cancer in cats, and it may also help improve how we treat cancer in ...
Novartis has committed up to $3 billion—two-thirds of that upfront—toward acquiring Pikavation Therapeutics, a subsidiary of Synnovation Therapeutics that specializes in developing PI3Kα inhibitor ...
It’s time once again for Fierce Pharma Marketing’s annual #FierceMadness tournament. This time around, we're watching 64 ...
Basel, March 20, 2026 – Novartis today announced that it has entered into an agreement with Synnovation Therapeutics, LLC to acquire SNV4818, a pan-mutant‑selective PI3Kα inhibitor, exploring a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results